LeMaitre Vascular, Inc.

NasdaqGM LMAT

LeMaitre Vascular, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD 60.35 M

LeMaitre Vascular, Inc. EBITDA is USD 60.35 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 36.70% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • LeMaitre Vascular, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 44.15 M, a 6.57% change year over year.
  • LeMaitre Vascular, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 41.43 M, a -14.65% change year over year.
  • LeMaitre Vascular, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 48.54 M, a 53.39% change year over year.
  • LeMaitre Vascular, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 31.65 M, a 9.67% change year over year.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Loading...
NasdaqGM: LMAT

LeMaitre Vascular, Inc.

CEO Mr. George W. LeMaitre
IPO Date Oct. 19, 2006
Location United States
Headquarters 63 Second Avenue
Employees 614
Sector Health Care
Industries
Description

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Similar companies

HAE

Haemonetics Corporation

USD 79.96

0.69%

NVST

Envista Holdings Corp

USD 18.85

-0.74%

UTMD

Utah Medical Products, Inc.

USD 61.49

0.77%

COO

The Cooper Companies, Inc.

USD 89.11

-2.38%

PDEX

Pro-Dex, Inc.

USD 45.00

-3.72%

KRMD

KORU Medical Systems, Inc.

USD 4.07

3.04%

ICUI

ICU Medical, Inc.

USD 161.08

1.85%

HOLX

Hologic, Inc.

USD 70.20

-0.13%

INFU

InfuSystem Holdings, Inc.

USD 7.87

-0.51%

StockViz Staff

January 15, 2025

Any question? Send us an email